Tonix Pharmaceuticals Holding Corp. has released an investor presentation outlining its current business and clinical development activities. As of September 30, 2025, the company reported approximately $190 million in cash and no debt, with an expected cash runway extending into the first quarter of 2027. Tonix currently has three FDA-approved products and focuses on therapeutic areas including central nervous system disorders and immunology. The presentation highlights the commercial launch of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, with wholesale acquisition costs set at $1,860 for a 60-count and $930 for a 30-count package. The company has deployed 90 sales representatives and established patient access programs. Key pipeline programs include TNX-1500 for prevention of organ transplant rejection, TNX-2900 for Prader-Willi Syndrome, and TNX-4800 for the seasonal prevention of Lyme disease, all in various stages of clinical development. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.